20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T61574 | PD-L1-IN-1 | ||
PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of periph... | |||
T9651 | PD-1/PD-L1-IN-9 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in... | |||
T9616 | PD-1/PD-L1-IN-10 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. | |||
T36899 | INCB086550 | PD-1/PD-L1-IN-8 | PD-1/PD-L1 |
INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. | |||
T36900 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1 |
PD-1/PD-L1-IN-NP19, a PD-1/PD-L1 inhibitor, exhibits an IC50 of 12.5 nM against the human PD-1/PD-L1 interaction, potentially activating the tumor immune microenvironment and contributing to its antitumor effects[1]. | |||
T36487 | Evixapodlin | PD-1/PD-L1-IN 7,GS-4224 | Antiviral , HBV , PD-1/PD-L1 |
Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. | |||
T12380 | PD-1/PD-L1-IN 5 TFA | PD-1/PD-L1-IN 5 | Others |
PD-1/PD-L1-IN 5 is an inhibitor of PD-1/PD-L1 protein/protein interaction (IC50 of ≤100 nM). | |||
TP1463 | PD-1/PD-L1-IN 3 TFA (1629654-95-0 free base) | PD-1/PD-L1-IN 3 TFA | |
PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM. | |||
T72670 | PD-1/PD-L1-IN-13 | ||
PD-1/PD-L1-IN-13 is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM for PD-1/PD- L1 interaction.PD-1/PD-L1-IN-13 promotes CD8+ T-cell activation and delays tumour growth in a Hepa1-6 homozyg... | |||
T62501 | PD-1/PD-L1-IN-17 | ||
PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 inhibitor (IC50: 26.8 nM). PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of PD-1/PD-L1 interactions. -17 has potential for cancer d... | |||
T63614 | PD-1/PD-L1-IN-15 | ||
PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy. | |||
T72675 | PD-1/PD-L1-IN-23 | ||
PD-1/PD-L1-IN-23 is a potent, orally active ester prodrug of L7, a benzooxadiazole derivative, and functions as an inhibitor of PD-1/PD-L1. It has been biologically evaluated for its inhibitory effects on PD-L1, demonstr... | |||
T79643 | PD-1/PD-L1-IN-33 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM. By doing so, it enhances T-cell proliferation, activation, and infiltration with... | |||
T72691 | PD-1/PD-L1-IN-28 | ||
PD-1/PD-L1-IN-28, an inhibitor of the PD-1/PD-L1 signaling pathway (IC 50 = 0.744 µM), demonstrates promising research potential in tumor immunity. This immune checkpoint inhibitor effectively blocks the interaction with... | |||
T63607 | PD-1/PD-L1-IN-22 | ||
PD-1/PD-L1-IN-22 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interactions that blocks PD-1/PD-L1 interactions (IC50: 0.732 μM). PD-1/PD-L1-IN-22 can be used to study cancer, infectious diseases and autoim... | |||
T61968 | PD-1/PD-L1-IN 6 | ||
PD-1/PD-L1-IN 6 (compound A13) is a potent inhibitor of PD-1/PD-L1 interaction (IC 50 = 132.8 nM). PD-1/PD-L1-IN 6 shows outstanding immunoregulatory activity. In a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, PD-1... | |||
T63329 | PD-1/PD-L1-IN-25 | ||
PD-1/PD-L1-IN-25 is an inhibitor of PD-1/PD-L1 interaction (IC50: 16.17 nM) that effectively activates anti-tumor immunity of T cells in PBMCs. PD-1/PD-L1-IN-25 can be used to study cancer. | |||
T79205 | PD-1/PD-L1-IN-34 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (K D = 0.1554 μM), resulting in the activation of the immune... | |||
T72668 | PD-1/PD-L1-IN-26 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-26 (Compound II-14) is a potent PD-1/PD-L1 inhibitor, demonstrating an IC50 of 0.0380 μM. It enhances the immune microenvironment by facilitating CD4+ T cell infiltration into tumor tissues, indicating pote... | |||
T72680 | PD-1/PD-L1-IN-27 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-27 is a potent inhibitor of PD-1/PD-L1, exhibiting an IC50 of 134 nM and demonstrating antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1]. |